Overview

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Status:
Recruiting

Trial end date:
2029-08-31

Target enrollment:

Participant gender:

Summary

This is a clinical trial using CPI-0209 in combination with Carboplatin chemotherapy followed by CPI-0209 maintenance in patients with platinum sensitive, recurrent ovarian cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Lan Coffman

Collaborators:

MorphoSys AG
National Cancer Institute (NCI)

Treatments:

Carboplatin